Previous 10 | Next 10 |
Despite being the most common vaginal condition, 1 BV symptoms are often mistaken for a yeast infection 2 Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by p...
2024-01-09 22:55:25 ET Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference Call January 9, 2024 16:30 ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Christophe...
2024-01-08 08:02:40 ET More on Organon Organon: What I'm Looking For In This 8% Yield In 2024 High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Organon: It's Darkest Before The Dawn EU suggests label update to flag brain-related...
Regular dividend to remain primary capital allocation priority For full year 2023, the company expects revenue and Adjusted EBITDA margin to be within the ranges provided on November 2, 2023 For full year 2023 the company expects free cash flow before one-time spin-related costs to ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-03 08:10:00 ET Summary Organon, a pharmaceutical company, has a diverse portfolio of products in women's health and biosimilars. The company has faced challenges in its women's health segment but expects a turnaround in its top-selling drug and growth in the fertility busi...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2024, at 1:30 p.m. PT. Investors, analys...
2023-12-21 01:08:28 ET Summary Pfizer stock has fallen 45% YTD as it has been impacted by the decline in revenue from COVID-19 products. The recent news about Danuglipron has added fuel to the fire. But is everything so bad when it comes to investing in the company for the long te...
2023-12-20 23:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an investigational Prolia ® and Xgeva ® (denosumab) biosimilar. Denosumab has been a...
2024-05-23 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...